ArticlePloS one2025

Cost-effectiveness analysis of benmelstobart and anlotinib plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: Perspectives from the United States and China.

Wenwang Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.